Safety and Efficacy of Oral Versus Intravenous Amiodarone in the Treatment of AF

• Status: Unknown status
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Atrial fibrillation (AF) remains a significant contributor to cardiovascular morbidity. Amiodarone is a potent antiarrhythmic drug; however, patients receiving IV amiodarone are at high risk for phlebitis. Phlebitis may lead to infection, additional medical intervention, delay in treatment, and prolonged hospitalization. Therefore, examining new therapy approach, aimed to reduce the incidence of phlebitis is a valuable clinical and research goal.

Aim: To evaluate the safety and efficacy of oral versus intravenous (IV) Amiodarone in the treatment of AF of recent onset (duration < 48 h).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Western Galilee Hospital-Nahariya
• Treatments: Amiodarone

Criteria

Inclusion Criteria:

• Over 18 years of age,

• Patients who will be admitted to the ICCU / ICU wards

• Patients with recent onset of atrial fibrillation (duration < 48h).

Exclusion Criteria:

• Age < 18 years

• Baseline systolic blood pressure < 100 mm/hg

• Known thyroid disease

• Serum potassium < 3.5 mmol/l

• Pretreatment with amiodarone

• Pregnant or lactating women.

• Participation in other clinical trial.